filing
saveXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
community read0 votes
Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion
Data sources
globaldata
Found something off?
drug timeline · 4
- filingXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))Apr 30, 2026 · 160d ago
- filingXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))Apr 30, 2026 · 160d ago
- filingXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))Apr 30, 2026 · 160d ago
- filingXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))Apr 30, 2026 · 160d ago
same company · ±60 days · 4
- filingranibizumab biosimilar: Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))Apr 30, 2026
- filingranibizumab biosimilar: Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))Apr 30, 2026
- filingranibizumab biosimilar: Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))Apr 30, 2026
- filingranibizumab biosimilar: Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))Apr 30, 2026
🐶 often sniffed alongside
top 8- tagApproval16 co-mentions · 8 sources
- drugBYOOVIZ16 co-mentions · 8 sources
- drugranibizumab13 co-mentions · 13 sources
- drugranibizumab SR13 co-mentions · 13 sources
- companySamsung Bioepis Co Ltd8 co-mentions · 8 sources
- companyXbrane Biopharma AB5 co-mentions · 5 sources
- tagOphthalmology5 co-mentions · 5 sources
- tagBiosimilar5 co-mentions · 5 sources
comments(0)
5-min edit window · permanent after that